The androgen receptor as an emerging target in hepatocellular carcinoma

Tatsuo Kanda
Osamu Yokosuka
Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, Chiba, Japan

Abstract: Hepatocellular carcinoma (HCC) is one of the male-dominant liver diseases with poor prognosis, although treatments for HCC have been progressing in the past decades. Androgen receptor (AR) is a member of the nuclear receptor superfamily. Previous studies reported that AR was expressed in human HCC and non-HCC tissues. AR is activated both ligand-dependently and ligand-independently. The latter is associated with a mitogen-activated protein kinase–, v-akt murine thymoma viral oncogene homolog 1–, or signal-transducer and activator of transcription–signaling pathway, which has been implicated in the development of HCC. It has been reported that more than 200 RNA expression levels are altered by androgen treatment. In the liver, androgen-responsive genes are cytochrome P450s, transforming growth factor β, vascular endothelial growth factor, and glucose-regulated protein 78 kDa, which are also associated with human hepatocarcinogenesis. Recent studies also revealed that AR plays a role in cell migration and metastasis. It is possible that cross-talk among AR-signaling, endoplasmic reticulum stress, and innate immune response is important for human hepatocarcinogenesis and HCC development. This review shows that AR could play a potential role in human HCC and represent one of the important target molecules for the treatment of HCC.

Keywords: vascular endothelial growth factor, angiogenesis, glucose-regulated protein 78 kDa, hepatocarcinogenesis, molecular targets

Introduction

Hepatocellular carcinoma (HCC) is one of the male-dominant cancers with poor prognosis, although treatments are being developed.1,4 HCC usually occurs after the age of 40 years, reaching a peak at approximately 70 years of age.6 Irrespective of their etiology, rates of HCC among men are two to four times higher than those among women.5 HCC derived from hepatitis B virus (HBV) or hepatitis C virus infection and virus-unrelated HCC are male-dominant disorders.6,7 Similar sex difference is also observed in mice given a chemical carcinogen, diethylnitrosamine.8

In humans, androgen and estrogen are essential sex steroid hormones involved in many cellular processes such as cell metabolism and cell differentiation, as well as sex development.9 Both androgen receptor (AR) and estrogen receptor α, for androgen and estrogen, respectively, seem to be involved in hepatocellular carcinogenesis.8,10–12 There have been many reports concerning the expression of AR in HCC and its surrounding liver tissues.13–31 The association between AR and liver diseases is shown in Table 1. In this review article, we provide comprehensive insights regarding the association between ARs and HCC. We have been expecting that AR would become an emerging therapeutic target in HCC.
**Table 1** Androgen receptor (AR) and liver diseases from different etiologies

| Etiology of HCC | Roles of AR | References |
|-----------------|-------------|------------|
| HBV | AR-CAG repeats may be associated with an increased risk of HCC | 116 |
| HBV | AR signaling may affect the risk of HBV-related HCC among men | 117 |
| HBV | AR exon 1 CAG repeat length may contribute to HCC predisposition among women | 118,119 |
| HBV | TNR of AR gene in male HCC | 120 |
| HBV | HBx enhances AR-responsive gene expression | 10,11,121–123 |
| HBV | AR promotes HBV replication | 124–126 |
| HBV | CCRK-AR regulates HBV-associated HCC | 127 |
| HCV | HCV core augments AR-signaling | 12 |
| NAFLD | Association between AR, ER stress, and hepatic lipid deposition | 86,128–130 |
| Alcohol | AR associated with severity of liver diseases | 56 |

**Abbreviations:** HCC, hepatocellular carcinoma; HBV, hepatitis B virus; TNR, trinucleotide repeats; HBx, hepatitis B virus X; AR, androgen-responsive; HCV, hepatitis C virus; NAFLD, nonalcoholic fatty liver disease; ER, endoplasmic reticulum; CCRK, cell cycle–related kinase.

### ARs and androgen action

Human AR is a member of the nuclear steroid receptor superfamily and AR gene is located on Xq11-12, indicating that males have a single copy of the gene.32 AR is a ligand-activated transcriptional factor with three domains: DNA-binding domain, C-terminal ligand-binding domain, and N-terminal transactivation domain.33 Unliganded AR is inactive and is bound to cytoplasmic chaperones such as heat shock protein 90 (Hsp90).34 Testosterone is produced in the testes and is converted to dihydrotestosterone. Ligands bind to AR and activate AR, inducing conformational change. Then, the AR dimerizes and the AR-dimers translocate to the nucleus, where AR binds to consensus-binding sequences (androgen-responsive elements [AREs]) in the DNA to regulate target gene expression.34 Mitogen-activated protein kinase (MAPK)/extracellular signal–regulated protein kinase signaling increases the stability of AR.34 Interleukin-6 is sufficient to activate AR in vitro, and steroid receptor coactivator-1 has been shown in interleukin-6–dependent signaling.35 Steroid receptor coactivator-1 has been shown to interact with human AR and to modulate ligand-dependent AR transactivation, and it is regulated by phosphorylation by MAPK.35 Growth and survival pathways such as MAPK, v-akt murine thymoma viral oncogene homolog 1 (AKT), and signal-transducer and activator of transcription (STAT) signaling are involved in the ligand-independent activation of AR of prostate cancer, pancreatic cancer, and HCC.12,35–40 It is also known that MAPK, AKT, and STAT could activate AR signaling, and they also are involved in human hepatocarcinogenesis.41–48 In several human cancers, AR seems to be activated in an androgen-dependent and/or androgen-independent manner (Figure 1).

### Target genes of AR in the liver AR and its target genes

Androgens and steroid hormones bind to the AR and, in turn, AR associates with genomic AREs (Table 2).49 In LNCap prostate cancer cells, more than 200 RNA expression levels are altered by androgen treatment.49,51 Androgen plays a critical role for the cytoskeleton and extracellular matrix in transducing signals for growth, differentiation, and secretion in normal and cancerous prostate cells.50,52 Upregulation of NF-kB and several DNA repair or stress-response gene expressions may be a secondary response to oxidative stress rather than a direct response to AR signaling.50,53 Bolton et al49 reported that most androgen-responsive genes (ARGs) were associated with two or more AREs and that ARGs were sometimes themselves linked in gene clusters containing up to 13 AREs and 12 ARGs. Primary ARGs seem to produce effects on secondary target genes.50

### Androgen and the liver

Human liver microsomes and cytochrome P450s (CYP) are major sites of metabolism of drugs and hormones. The liver could have an impact on the metabolism of androgen and the activation of AR or on the metabolism of anti-androgenic drugs such as flutamide.54,55 It was reported that downregulation of AR activity correlates with the severity of alcoholic liver injury.56 Hepatocyte nuclear factor-1 and CCAAT/enhancer-binding protein are responsible for liver specificity of the rat dehydroepiandrosterone sulfotransferase gene, which catalyzes sulfonation of androgenic steroids and certain aromatic procarcinogens.57

### AR and transforming growth factor β1 (TGF-β1) in the liver

TGF-β1 expression increases during progression of HCC,58,59 hepatic cirrhosis,60,61 hepatic damage,62,63 and hepatic regeneration.64,65 Yoon et al66 found that the promoter region of TGF-β1 includes putative androgen response sequence and also in vivo and in vitro evidence of activation of TGF-β1 expression by androgen and AR. They reported that androgen might regulate hepatocarcinogenesis by increasing...
transcription of TGF-β1 through direct interactions with AR and ARE in the TGF-β1 gene.66

**AR and cholesterol homeostasis in the liver**

AR signaling plays a role in the development and progression of several liver diseases, including HCC and nonalcoholic fatty liver disease. Androgen control of growth hormone secretion also induces male-specific genes in the liver.67 AR activation results in obesity and altered lipid metabolism in orchidectomized mice,68 suggesting that the activation of AR might be involved in HCC development in patients with nonalcoholic steatohepatitis, although there is also a contrary opinion.69 But these studies showed that hepatic AR may play a role in the development of insulin resistance and hepatic steatosis.65,69 CYP27A1 is a key enzyme in cholesterol homeostasis and vitamin D₃ metabolism. AR could induce CYP27A1, which is a target for the JNK/c-Jun pathway. The JNK/c-Jun pathway is thought to be involved in AR-mediated upregulation of human CYP27A1.70 Krycer and Brown71 showed that liver-X-receptor activity is down-regulated by AR. The cross-talk between AR and liver-X-receptor is important for cholesterol homeostasis.

**AR and hepatocarcinogenesis**

Vascular endothelial growth factor (VEGF) is a target gene of AR49 and plays an important role in angiogenesis in the liver.12 Hepatitis C virus core protein enhances AR signaling, upregulates VEGF expression in hepatocytes, and facilitates angiogenesis.12 VEGF is one of the key molecules of treatment of HCC.72,73 Of interest, female sex was associated with better response to sorafenib in patients with unresectable HCC in Japan.74 Feng et al reported that cell cycle–related kinase is a direct AR transcriptional target and that cell cycle–related kinase promotes hepatocarcinogenesis through the upregulation of β-catenin/TCF signaling.75
AR and aryl hydrocarbon (or dioxin) receptor

Both aryl hydrocarbon (or dioxin) receptor and aryl hydrocarbon (or dioxin) receptor nuclear translocator are known to interact with AR. AR might also be involved in hepatocarcinogenesis through aryl hydrocarbon (or dioxin) receptor pathways. Li et al reported that the vertebral forkhead box A factors and their targets estrogen receptor α and AR play an important role in the sex difference of HCC. Nuclear receptors including AR and estrogen receptor and their related signaling pathways play a role in human hepatocarcinogenesis.

AR and cell migration

Recent studies revealed that AR is involved in cell migration and metastasis. At present, it is not clear whether AR could promote cell migration or not. Although further studies will be needed regarding this point, AR is one of the important target molecules for treatment targeting metastasis or advanced HCC.

AR and endoplasmic reticulum stress

Dihydrotestosterone could induce RNA-dependent protein kinase/eukaryotic initiation factor-2α activation in human hepatocytes. Dai et al reported that RNA-dependent protein kinase/eukaryotic initiation factor-2α activation is involved in dihydrotestosterone-induced cell cycle arrest and that the eukaryotic initiation factor-2α/GADD153 pathway, a branch of ER stress response, is enhanced. It is well known that the ER stress pathway is involved in human hepatocarcinogenesis.

AR and Toll-like receptor signaling pathways

Tissue expression of AR is associated with differential immune responsiveness. Toll-like receptors (TLRs) are a family of transmembrane receptors and play central roles in innate immunity. TLR4 recognizes lipopolysaccharide, a cell wall component of gram-negative bacteria that activate innate immunity. Lipopolysaccharide induced apoptosis in hepatocytes and reduced the hepatic expressions of ER stress–related proteins. ER stress response is important for hepatic cell damage from an innate immune response.

Testosterone downregulated the expression of several TLR genes, possibly resulting in the inhibition of the immune response. MyD88, downstream of TLR4, may play a role in limiting prostate tumorigenesis by altering tumor-infiltrating immune populations. We observed an increase of lipopolysaccharide-induced apoptosis (67%) in HepG2 stably expressing shAR as compared to that (47%) in HepG2 control cells. AR and ER stress response may be involved in innate immune response of hepatocytes.

AR and other signaling pathways

Several reports indicated that insulin-like growth factor (IGF), fibroblast growth factor (FGF), and VEGF, as well as mammalian target of the rapamycin (mTOR) signaling pathways are involved in human hepatocarcinogenesis. Cell surface receptors for IGF, FGF, and VEGF activate downstream signal transduction through the receptor-tyrosine kinases. These receptors are also important molecular targets for drugs against HCC such as sorafenib, brivanib, and everolimus.

IGF-1 and its binding proteins are also known as AR-targeting genes in prostate cancer cells. Tsuei et al showed that downregulation of IGF-1 and its binding protein-3 were observed in the RNA-binding motif gene on the Y chromosome–knockdown HepG2 cells, suggesting the enhancing effect of RNA-binding motif gene on the Y chromosome on AR transactivation activity in human HCC.

AR could control FGF and FGF-binding protein production and affect FGF signaling pathway in prostate cancer cells. AR may have an impact on FGF signaling pathway as well as VEGF signaling pathways in human hepatocarcinogenesis. PI3K/phosphatase and tensin homologs deleted on chromosome 10 (PTEN)/Akt/mTOR pathway are involved in many cellular processes of human HCC.
AR in HCC

A previous study in prostate cancer cell lines showed AR-mTOR cross-talk is regulated by testosterone availability. Further study will be needed at a significance of AR-mTOR cross-talk in human hepatocarcinogenesis.

HBV and AR

Chen and Yebs’ group has extensively studied the association between HBV infection and AR, or the association between HBx protein and AR, and reported that AR is involved in human hepatocarcinogenesis. Table 1 shows several mechanisms of the effects of AR in HBV-associated HCC. Many studies with human liver tissues also support this concept. These data support the idea that AR could be one of the important molecular targets for the treatment of HCC with or without HBV infection.

Table 3 Clinical trials targeting androgen in hepatocellular carcinoma

| Drug (dosage) | Randomized study | Number of patients | Eligibility | Stage of HCC | Efficacy: mean survival or response | Ref |
|---------------|------------------|--------------------|-------------|--------------|------------------------------------|-----|
| Leuprorelin, flutamide, and tamoxifen | Yes | 192 | Child-Pugh Class A/B/C: 112/50/2; cirrhosis, 90%; ascites, 26%; HBV, 3%; HCV, 19% | Okuda’s classification stage III/IV: 81/107/4 | 135.5 d (P=0.21) | 108 |
| Tamoxifen (administered until death) | Yes | 184 | Child-Pugh Class A/B/C: 105/59/5; cirrhosis, 93%; ascites, 31%; HBV, 10%; HCV, 13% | Okuda’s classification stage III/IV: 93/83/8 | 176 d | 108 |
| Flutamide for 8 weeks | Phase II | 32 | Measurable advanced HCC patients; hepatitis-related, 88% | A/JCC stage III/IV: 5/27 | 10 wks; 9 of 22 (41%), stable diseases; 13 (59%), progress diseases | 109 |
| Antiandrogen (Anandron) plus placebo | Yes | 58 | Unresectable HCC; cirrhosis, 76%; HBV, 25% | N/A | 3.6 mo (NS); 1, complete response | 110 |
| LHRH agonist plus placebo | Yes | 61 | Unresectable HCC; cirrhosis, 85%; HBV, 21% | N/A | 2.7 mo (NS); 1, partial response | 110 |
| Antiandrogen plus LHRH agonist | Yes | 60 | Unresectable HCC; cirrhosis, 82%; HBV, 14% | N/A | 3.9 mo (NS); 1, partial response | 110 |
| Placebo plus placebo | Yes | 59 | Unresectable HCC; cirrhosis, 83%; HBV, 35% | N/A | 5.8 mo | 110 |
| Cyproterone acetate | No | 25 | Cirrhotics with unresectable HCC | N/A | 14 wks; 5, excess in 29 wks; 5, response | 111 |
| Ketoconazole | No | 8 | Unresectable HCC | N/A | 6, <8 weeks | 112 |
| D-Tryptophan-6-luteinizing hormone-releasing hormone | No | 17 | Cirrhotics with HCC | N/A | No response | 113 |
| LHRH-analog triptorelin and tamoxifen | Yes | 33 | Child-Pugh: 7.7±2.0 (untreated HCC); cirrhosis, 27; HBsAg (+), 69.7%; anti-HDV (+), 15.2%; anti-HCV (+), 12.1% | Okuda stage III/IV (%): 27.3/18.2 | 282 d (P=0.020 vs placebo) | 114 |
| Triptorelin plus flutamide | Yes | 23 | Child-Pugh: 8.3±1.6 (untreated HCC); cirrhosis, 18; HBsAg (+), 56.5%; anti-HDV (+), 8.7%; anti-HCV (+), 8.7% | Okuda stage III/IV (%): 21.7/13.0 | 112 d (NS vs placebo) | 114 |
| Placebo | Yes | 29 | Child-Pugh: 8.9±2.1 (untreated HCC); cirrhosis, 25; HBsAg (+), 58.6%; anti-HDV (+), 10.7%; anti-HCV (+), 20.0% | Okuda stage III/IV (%): 24.1/17.2 | 127 d | 114 |

Abbreviations: AJCC, American Joint Committee on Cancer; HBV, hepatitis B virus; HCV, hepatitis C virus; HDV, hepatitis delta virus; HBsAg, hepatitis B virus surface antigen; LHRH, luteinizing hormone-releasing hormone; HCC, hepatocellular carcinoma; Ref, references; NS, not significant; N/A, not applicable; d, days; wks, weeks; mo, months; vs, versus.
Further studies concerning AR and ARGs in the liver should be carried out.

Acknowledgments

This work was supported by a KAKEN Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (24590955).

Disclosure

The authors report no conflicts of interest in this work.

References

1. Yamashita YI, Yoshida Y, Kunihara T, et al. Surgical results for recurrent hepatocellular carcinoma after curative hepatectomy: repeat hepatectomy vs salvage living donor liver transplantation. Liver Transpl. 2015.
2. Llovet JM, Ricci S, Mazzaferro V, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390.
3. Furuse I, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci. 2008;99(1):159–165.
4. Shiina S, Tateishi R, Arano T, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol. 2012;107(4):569–577.
5. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118–1127.
6. Shiratori Y, Shina S, Imamura M, et al. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C-viral infection in Japan. Hepatology. 1995;22(4 pt 1):1027–1033.
7. Tateishi R, Okanoue T, Fujiwara N, et al. Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study. J Gastroenterol. 2015;50(3):350–360.
8. Naugler WE, Sakurai T, Kim S, et al. Augmentation androgen receptor-mediated signaling. Proc Natl Acad Sci U S A. 2007;104(2):2571–2578.
9. Zhao Y, Li Z. Interplay of estrogen receptors and FOXA factors in the liver cancer. Mol Cell Endocrinol. 2015.
10. Chiu CM, Yeh SH, Chen PJ, et al. Hepatitis B virus X protein enhances androgen receptor-responsive gene expression depending on androgen level. Proc Natl Acad Sci U S A. 2007;104(8):3571–3575.
11. Zheng Y, Chen WL, Ma WL, Chang C, Ou JH. Enhanced expression of gene transactivation activity of androgen receptor by hepatitis B virus X protein. Virology. 2007;363(2):454–461.
12. Kanda T, Steele R, Ray R, Ray RB. Hepatitis C virus core protein augments androgen receptor-mediated signaling. J Virol. 2008;82(22):11066–11072.
13. Iqbal MJ, Wilkinson ML, Johnson PJ, Williams R. Sex steroid receptor proteins in foetal, adult and malignant human liver tissue. Br J Cancer. 1983;48(6):791–796.
14. Wong LY, Chan SH, Oon CJ, Rauff A. Immunocytochemical localization of testosterone in human hepatocellular carcinoma. Histochim J. 1984;16(6):687–692.
15. Nagasue N, Yukawa H, Chang YC, Ogawa Y, Kohno H, Ito A. Active uptake of testosterone by androgen receptors of hepatocellular carcinoma in humans. Cancer. 1986;57(11):2162–2167.
16. Nagasue N, Ito A, Yukawa H, Ogawa Y. Androgen receptors in hepatocellular carcinoma and surrounding parenchyma. Gastroenterology. 1985;89(3):643–647.
17. Wilkinson ML, Iqbal MJ, Williams R. Characterisation of high affinity binding sites of androgens in primary hepatocellular carcinoma. Clin Chim Acta. 1985;152(1–2):105–113.
18. Ohnishi S, Murakami T, Moriyama T, Mitamura K, Imawari M. Androgen and estrogen receptors in hepatocellular carcinoma and in the surrounding noncancerous liver tissue. Hepatology. 1986;6(3):440–443.
19. Bannister P, Meystre CM, Losowski MS. Androgen receptor concentrations in needle biopsy specimens of human liver. Liver. 1988;8(1):28–31.
20. Nagasue N, Kohno H, Chang YC, et al. Androgen and estrogen receptors in hepatocellular carcinoma and the surrounding liver in women. Cancer. 1989;63(1):112–116.
21. Nagasue N, Chang YC, Hayashi T, et al. Androgen receptor in hepatocellular carcinoma as a prognostic factor after hepatic resection. Ann Surg. 1989;209(4):424–427.
22. Nagasue N, Kohno H, Chang Y, Hayashi T, Nakamura T. Specificity of androgen receptors of hepatocellular carcinoma and liver in humans. Hepatogastroenterology. 1990;37(5):474–479.
23. Nagasue N, Kohno H, Yamanoi A, Kimoto T, Chang YC, Nakamura T. Progesterone receptor in hepatocellular carcinoma. Correlation with androgen and estrogen receptors. Cancer. 1991;67(10):2501–2505.
24. Eagon PK, Francavilla A, DiLeo A, et al. Quantification of estrogen and androgen receptors in hepatocellular carcinoma and adjacent normal human liver. Dig Dis Sci. 1991;36(9):1303–1308.
25. Nagasue N, Yamanoi A, Kohno H, et al. Androgen receptor in cirrhotic liver, adenomatous hyperplastic nodule and hepatocellular carcinoma in the human. Hepatogastroenterology. 1992;39(5):455–460.
26. Boix L, Bruix J, Castells A, et al. Sex hormone receptors in hepatocellular carcinoma. Is there a rationale for hormonal treatment? J Hepatol. 1993;17(2):187–191.
27. Negro F, Papotti M, Pacchioni D, Galimi F, Bonino F, Bussolati G. Detection of human androgen receptor mRNA in hepatocellular carcinoma by in situ hybridisation. Liver. 1994;14(4):213–219.
28. Boix L, Castells A, Bruix J, et al. Androgen receptors in hepatocellular carcinoma and surrounding liver: relationship with tumor size and recurrence rate after surgical resection. J Hepatol. 1995;22(6):616–622.
29. Tavian D, De Petro G, Pitozzi A, Portolani N, Giuliani SM, Barlati S. Androgen receptor mRNA under-expression in poorly differentiated human hepatocellular carcinoma. Histol Histopathol. 2002;17(4):1113–1119.
30. Vizoso FJ, Rodriguez M, Altadill A, et al. Liver expression of steroid hormones and apolipoprotein D receptors in hepatocellular carcinoma. World J Gastroenterol. 2007;13(23):3221–3227.
31. Zhang Y, Shen Y, Cao B, Yan A, Ji H. Elevated expression levels of androgen receptors and matrix metalloproteinase-2 and -9 in 30 cases of hepatocellular carcinoma compared with adjacent tissues as predictors of cancer invasion and staging. Exp Ther Med. 2015;9(3):905–908.
32. Hughes IA, Davies JD, Bunch TI, Pasterski V, Mastroyannopoulos K, MacDougall J. Androgen insensitivity syndrome. Lancet. 2012;380(9851):1419–1428.
33. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol. 2002;20(13):3001–3015.
34. Shafi AA, Tran AE, Weigel NL. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacol Ther. 2013;140(3):223–238.
35. Ueda T, Mawji NR, Bruchovsky N, Sadar MD. Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem. 2002;277(41):38087–38094.
36. Kulig Z, Hobisch A, Cronauer A, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocye growth factor, and epidermal growth factor. Cancer Res. 1994;54(20):5474–5478.
37. Okitsu K, Kanda T, Imazeki F, et al. Involvement of interleukin-6 and androgen receptor signaling in pancreatic cancer. Genes Cancer. 2010;1(8):859–867.
38. Kanda T, Yokosuka O, Omata M. Androgen receptor and hepatocellular carcinoma. J Gastroint Dig Syst. 2013:S12.
39. Kanda T, Jiang X, Yokosuka O. Androgen receptor signaling in hepatocellular carcinoma and pancreatic cancers. World J Gastroenterol. 2014;20(28):9229–9236.

40. Wu S, Kanda T, Imazeki F, Nakamoto S, Shirasawa H, Yokosuka O. Nuclear receptor mRNA expression by HBV in human hepatoblastoma cell lines. Cancer Lett. 2011;312(1):33–42.

41. Tanaka S, Mohr L, Schmidt EV, Sugimachi K, Wands JR. Biological effects of human insulin receptor substrate-1 overexpression in hepatocytes. Hepatology. 1997;26(3):598–604.

42. Ito Y, Sasaki Y, Horimoto M, et al. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology. 1998;27(4):951–958.

43. Suzuki A, Hayashida M, Kawano H, Sugimori K, Nakano T, Shiraki K. Hepatocyte growth factor promotes cell survival from fas-mediated cell death in hepatocellular carcinoma cells via Akt activation and Fas-death-inducing signaling complex suppression. Hepatology. 2000;32(4 pt 1):796–802.

44. Fujimaki S, Matsuda Y, Wakai T, et al. Blockade of ataxia telangiectasia mutated sensitizes hepatoma cell lines to sorafenib by interfering with Akt signaling. Cancer Lett. 2012;319(1):98–108.

45. Sato M, Matsuda Y, Wakai T, et al. P21-activated kinase-2 is a critical mediator of transforming growth factor-beta-induced hepatoma cell migration. J Gastroenterol Hepatol. 2013;28(6):1047–1055.

46. Matsuda Y, Wakai T, Kubota M, et al. Valproic acid overcomes transforming growth factor-beta-mediated sorafenib resistance in hepatocellular carcinoma. Int J Clin Exp Pathol. 2014;7(4):1299–1313.

47. Yoshikawa H, Matsubara K, Qian GS, et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet. 2001;28(1):29–35.

48. Kanda T, Jiang X, Yokosuka O. Androgen receptor signaling in hepatocellular carcinoma and shows growth-suppression activity. Nat Genet. 2001;28(1):29–35.

49. Krycer JR, Brown AJ. Cross-talk between the androgen receptor and the aryl hydrocarbon receptor-regulated gene that drives hepatocarcinogenesis. J Cell Biochem. 2011;286(23):20637–20647.

50. DePrimo SE, Diehn M, Nelson JB, et al. Transcriptional programs of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma. In: Qiao L, Yan X, Li Y, George Y, editors. World J Gastroenterol. 2011;286(23):20637–20647.

51. Nelson PS, Clegg N, Arnhold H, et al. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci U S A. 2002;99(18):11890–11895.

52. Getzenberg RH, Pienta KJ, Ward WS, Coffey DS. Nuclear structure and the three-dimensional organization of DNA. J Cell Biochem. 1991;47(4):289–299.

53. Ripple MO, Henry WF, Schwarze SR, et al. Anti-atherogenic enzyme CYP27A1 involves the activation of the aryl hydrocarbon receptor. Proc Natl Acad Sci U S A. 2005;102(17):5985–5990.

54. Shchekin P, Domez H, Clement P, et al. Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. Ann Oncol. 2006;17(8):1185–1196.

55. Kudo M, Ueshima K. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan. Oncology. 2010;78(Suppl 1):154–166.

56. Takeda H, Nishikawa H, Osaki Y, et al; Japanese Red Cross Liver Study Group. Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan. Liver Int. 2015;35(5):1581–1589.

57. Feng H, Cheng AS, Tsang DP, et al. Cell cycle-related gene is a direct androgen receptor-regulated gene that drives J-catenin/T cell factor-dependent hepatocarcinogenesis. J Clin Invest. 2011;121(8):3159–3175.

58. Eagon PK, Elm MS, Tadic SD, Nanji AA. Downregulation of nuclear sex steroid receptor activity correlates with severity of alcoholic liver injury. Am J Physiol Gastrointest Liver Physiol. 2001;281(2):G342–G349.

59. Song CS, Jung MH, Kim SC, Hassan T, Roy AK, Chatterjee B. Tissue-specific and androgen-repressible regulation of the estrogen receptors α and β in human hepatocellular carcinoma. Cancer Res. 1991;51(15):4080–4083.

60. Nagahara H, Ezhevsky SA, Vocero-Akbani AM, Kaldis P, Solomon MJ, Dowdy SF. Transforming growth factor beta targeted inactivation of cyclin E/cyclin-dependent kinase 2 (Cdk2) complexes by inhibition of Cdk2 activating kinase activity. Proc Natl Acad Sci U S A. 1999;96(26):14961–14966.

61. Roberts AB, Sporn MB, Aasian RK, et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A. 1986;83(12):4167–4171.

62. Tsukamoto H, Matsuoka M, French SW. Experimental models of hepatic fibrosis: a review. Semin Liver Dis. 1990;10(1):56–65.

63. Yager JD, Zurlo J, Ni N. Sex hormones and tumor promotion in liver. Proc Soc Exp Biol Med. 1991;198(2):667–674.

64. Lin JK, Chou CK. In vitro apoptosis in the human hepatoma cell line induced by transforming growth factor beta 1. Cancer Res. 1992;52(2):385–388.

65. Fausto N, Mead JE, Braun L, et al. Proto-oncogene expression and growth factors during liver regeneration. Sysmimped Cancer Res. 1986;39:69–86.

66. Braun L, Mead JE, Panzica M, Mikumo R, Bell GI, Fausto N. Transforming growth factor beta mRNA increases during liver regeneration: a possible paracrine mechanism of growth regulation. Proc Natl Acad Sci U S A. 1988;85(5):1539–1543.

67. Yoon G, Kim JY, Choi YK, Won YS, Lim IK. Direct activation of TGF-beta1 transcription by androgen and androgen receptor complex in HuH7 human hepatoma cells and its tumor in nude mice. J Cell Biochem. 2006;97(2):393–411.

68. Robins DM. Androgen receptor and molecular mechanisms of male-specific gene expression. Novartis Found Symp. 2005;268:42–52.

69. Moväré-Skrtic S, Venken K, Andersson N, et al. Dihydrotestosterone treatment results in obesity and altered lipid metabolism in orchidectomized mice. Obesity (Silver Spring). 2006;14(4):662–672.

70. Lin HY, Yu IC, Wang RS, et al. Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor. Hepatology. 2008;47(6):1924–1935.

71. Norlin M, Pettersson H, Tang W, Wikvall K. Androgen receptor-mediated regulation of the anti-atherogenic enzyme CYP27A1 involves the JNK/c-jun pathway. Arch Biochem Biophys. 2011;506(2):236–241.

72. Krycer JR, Brown AJ. Cross-talk between the androgen receptor and the liver X receptor: implications for cholesterol homeostasis. J Biol Chem. 2011;286(23):20637–20647.

73. Ohlfski P, Domez H, Clement P, et al. Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. Ann Oncol. 2006;17(8):1185–1196.

74. Kudo M, Ueshima K. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan. Oncology. 2010;78(Suppl 1):154–166.

75. Takeda H, Nishikawa H, Osaki Y, et al; Japanese Red Cross Liver Study Group. Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan. Liver Int. 2015;35(5):1581–1589.

76. Feng H, Cheng AS, Tsang DP, et al. Cell cycle-related gene is a direct androgen receptor-regulated gene that drives J-catenin/T cell factor-dependent hepatocarcinogenesis. J Clin Invest. 2011;121(8):3159–3175.

77. Krüger T, Long M, Bonefeld-Jørgensen EC. Plastic components affect sex hormone and Fas-death-inducing signaling complex suppression. Cell Biol Int. 2011;35(5):1391–1398.

78. Li Z, Tuteja G, Schug J, Kaestner KH. Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer cell proliferation, invasion and metastasis. Mol Med Rep. 2013;8(4):999–1004.
80. Ma WL, Hsu CL, Yeh CC, et al. Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis. *Hepatology*. 2012;56(1):176–185.

81. Ao J, Meng J, Zhu L, et al. Activation of androgen receptor induces ID1 and promotes hepatocellular carcinoma cell migration and invasion. *Mol Oncol*. 2012;6(5):507–515.

82. Huang CK, Lee SO, Lai KP, et al. Targeting androgen receptor in bone marrow mesenchymal stem cells helps to better transplantation therapy efficacy in liver cirrhosis. *Hepatology*. 2013;57(4):1550–1563.

83. Nie H, Cao Q, Zhu L, Gong Y, Gu J, He Z. Acetylcholine acts on androgen receptor to promote the migration and invasion but inhibit the apoptosis of human hepatocarcinoma. *PLoS One*. 2013;8(4):e61678.

84. Ma WL, Lai HC, Yeh S, Cai X, Chang C. Androgen receptor roles in hepatocellular carcinoma, fatty liver, cirrhosis and hepatitis. *Endocr Relat Cancer*. 2014;21(3):R165–R182.

85. Ma WL, Jeng LB, Lai HC, Liao PY, Chang C. Androgen receptor enhances cell adhesion and decreases cell migration via modulating β1-integrin-Akt signaling in hepatocellular carcinoma cells. *Cancer Lett*. 2014;351(1):64–71.

86. Dai R, Yan D, Li J, et al. Activation of PKR/eIF2α signaling cascade is associated with dihydrotestosterone-induced cell cycle arrest and apoptosis in human liver cells. *J Cell Biochem*. 2012;113(5):1800–1808.

87. Shuda M, Kondoh N, Imazeki N, et al. Activation of the ATF6, XBPI and grp78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway in hepatocarcinogenesis. *J Hepatol*. 2003;38(5):605–614.

88. Tan SS, Ahmad I, Bennett HL, et al. GRP78 up-regulation is associated with androgen receptor status, Hsp70-Hsp90 client proteins and castrate-resistant prostate cancer. *J Pathol*. 2011;223(1):81–87.

89. Bennett HL, Fleming JT, O’Prey J, Ryan KM, Leung HY. Androgens modulate autophagy and cell death via regulation of the endoplasmic reticulum chaperone glucose-regulated protein 78/Bip in prostate cancer cells. *Cell Death Dis*. 2010;1:e72.

90. Kim SS, Cho HJ, Kang YJ, Kang HK, Yoo TK. Inhibition of androgen receptor expression with small interfering RNA enhances cancer cell apoptosis by suppressing survival factors in androgen insensitive, late stage LNCaP cells. *Cancer Lett*. 2013;346–348.

91. Jiang X, Kanda T, Nakamoto S, Miyamura T, Yoko SY, Kondo M. Involvement of androgen receptor and glucose-regulated protein 78 kDa in human hepatocarcinogenesis. *Exp Cell Res*. 2014;323(2):326–336.

92. Jia X, Tian T, Li D, et al. Androgen receptor up-regulation is associated with differential immune responsiveness. *Brain Behav Immun*. 2011;25(5):1000–1007.

93. Jiang X, Kanda T, Tanaka T, et al. Lipopolysaccharide blocks induction of unfolded protein response in human hepatoma cell lines. *Immunol Lett*. 2013;152(1):8–15.

94. Sánchez-Hernández M, Chaves-Pozo E, Cabas I, Calero J, García-Ayala A, García-Alcázar A. Testosterone implants modify the steroid hormone signaling cascade in male gilthead seabream (Sparus aurata L) males. *J Steroid Biochem Mol Biol*. 2012;138:185–194.

95. Sánchez-Hernández M, Chaves-Pozo E, Cabas I, Mulero V, García-Alcázar A. Testosterone implants modify the steroid hormone signaling cascade in male gilthead seabream (Sparus aurata L) males. *J Steroid Biochem Mol Biol*. 2012;138:185–194.

96. Sánchez-Hernández M, Chaves-Pozo E, Cabas I, Mulero V, García-Alcázar A. Testosterone implants modify the steroid hormone signaling cascade in male gilthead seabream (Sparus aurata L) males. *J Steroid Biochem Mol Biol*. 2012;138:185–194.

97. Sánchez-Hernández M, Chaves-Pozo E, Cabas I, Mulero V, García-Alcázar A. Testosterone implants modify the steroid hormone signaling cascade in male gilthead seabream (Sparus aurata L) males. *J Steroid Biochem Mol Biol*. 2012;138:185–194.

98. Sánchez-Hernández M, Chaves-Pozo E, Cabas I, Mulero V, García-Alcázar A. Testosterone implants modify the steroid hormone signaling cascade in male gilthead seabream (Sparus aurata L) males. *J Steroid Biochem Mol Biol*. 2012;138:185–194.
121. Zhu R, Zhang JS, Zhu YZ, et al. HBx-induced androgen receptor expression in HBV-associated hepatocarcinoma is independent of the methylation status of its promoter. Histol Histopathol. 2011;26:23–35.
122. Liu B, Wen X, Huang C, Wei Y. Unraveling the complexity of hepatitis B virus: from molecular understanding to therapeutic strategy in 50 years. Int J Biochem Cell Biol. 2013;45:1987–1996.
123. Yang WJ, Chang CJ, Yeh SH, et al. Hepatitis B virus X protein enhances the transcriptional activity of the androgen receptor through c-Src and glycogen synthase kinase-3 beta kinase pathways. Hepatology. 2009;49(5):1515–1524.
124. Wang SH, Yeh SH, Lin WH, Wang HY, Chen DS, Chen PJ. Identification of androgen response elements in the enhancer I of hepatitis B virus: a mechanism for sex disparity in chronic hepatitis B. Hepatology. 2009;50(5):1392–1402.
125. Wu MH, Ma WL, Hsu CL, et al. Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription. Sci Transl Med. 2010;2(32):32ra35.
126. Tian Y, Kuo CF, Chen WL, Ou JH. Enhancement of hepatitis B virus replication by androgen and its receptor in mice. J Virol. 2012;86(4):1904–1910.
127. Yu Z, Gao YQ, Feng H, et al. Cell cycle-related kinase mediates viral-host signalling to promote hepatitis B virus-associated hepatocarcinogenesis. Gut. 2014;63(11):1793–1804.
128. Hogg K, Wood C, McNeilly AS, Duncan WC. The in utero programming effect of increased maternal androgens and a direct fetal intervention on liver and metabolic function in adult sheep. PLoS One. 2011;6(9):e24877.
129. Zhang H, Liu Y, Wang L, et al. Differential effects of estrogen androgen on the prevention of nonalcoholic fatty liver disease in the male rat. J Lipid Res. 2013;54(2):345–357.
130. Kelly DM, Nettleship JE, Akhtar S, et al. Testosterone suppresses the expression of regulatory enzymes of fatty acid synthesis and protects against hepatic steatosis in cholesterol-fed androgen deficient mice. Life Sci. 2014;109(2):95–103.